Successful Management of a Black Male With Psoriasis and Dyspigmentation Treated With Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion: Case Report

October 2020 | Volume 19 | Issue 10 | Case Reports | 1000 | Copyright © October 2020


Published online October 2, 2020

Seemal R. Desai MD,a,b Andrew F. Alexis MD MPH,c Abby Jacobson MS PA-Cd

aInnovative Dermatology, PA, Plano, TX bDepartment of Dermatology, The University of Texas Southwestern Medical Center, Dallas, TX cDepartment of Dermatology, Mount Sinai Morningside and Mount Sinai West, New York, NY dOrtho Dermatologics*, Bridgewater, NJ *Ortho Dermatologics is a division of Bausch Health US, LLC

23. Cheyasak N, Manuskiatti W, Maneeprasopchoke P, Wanitphakdeedecha R. Topical corticosteroids minimise the risk of postinflammatory hyperpigmentation after ablative fractional CO2 laser resurfacing in Asians. Acta Derm Venereol. 2015;95(2):201-205.
24. Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: A double-blind, randomized, vehicle-controlled study. Cutis. 2006;77(1):45-50.
25. Tanghetti E, Dhawan S, Green L, et al. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris. J Drugs Dermatol. 2010;9(5):549-558.
26. Leyden J, Stein-Gold L, Weiss J. Why topical retinoids are mainstay of therapy for acne. Dermatol Ther (Heidelb). 2017;7(3):293-304.
27. Chandraratna RA. Tazarotene: The first receptor-selective topical retinoid for the treatment of psoriasis. J Am Acad Dermatol. 1997;37(2 Pt 3):S12-17.
28. Lebwohl MG, Sugarman JL, Gold LS, et al. Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019;80(1):282-285.

AUTHOR CORRESPONDENCE

Seemal R. Desai MD seemald@yahoo.com
Close Menu